BMED
Future Health ETF
BMED is actively managed to invest in global equities in the health sciences industry.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 11.1 M
ASSETS UNDER MGMT
85 bp
EXPENSES
Fund Basics
| Inception date | Sep 29, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| MERCK & CO. INC. | 5.6 % |
| GILEAD SCIENCES INC | 5.0 % |
| JOHNSON & JOHNSON | 5.0 % |
| EDWARDS LIFESCIENCES CORP | 4.9 % |
| MODERNA, INC. | 3.7 % |
| BIOGEN IDEC INC | 3.7 % |
| THERMO FISHER SCIENTIFIC INC | 3.7 % |
| DANAHER CORP | 3.6 % |
| WATERS CORP | 3.6 % |
| AMGEN INC | 3.4 % |
Constituent Breakdown
| Number of holdings | 61 |
| Herfindahl-Hirschman Index | 312 |
| Wgt avg mkt cap (mns) | $80,116 |
| Large cap (>$10bn) | 78.8% |
| Mid cap ($2-10bn) | 13.6% |
| Small cap (<$2bn) | 0.7% |
| Developed mkts. | 92.1% |
| Emerging mkts. | 1.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 83.6 % |
 |
SWITZERLAND | 3.1 % |
 |
BELGIUM | 1.6 % |
 |
BRITAIN | 1.5 % |
 |
NETHERLANDS | 1.1 % |
 |
CHINA | 1.0 % |
 |
IRELAND | 0.8 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -5.2% | 17.5% | 7.8% | 6.9% | -0.2% | -- | -- | 2.1% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | 0.0% |
| Total Returns | -5.2% | 17.5% | 7.8% | 6.9% | -0.2% | -- | -- | 2.1% | Ann. Volatility | 16.6% | 15.2% | 16.7% | 15.8% | 17.4% | -- | -- | 17.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.72 | 30% |
| MSCI EAFE | 0.64 | 37% |
| MSCI Emg Mkts | 0.37 | 21% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.30% |
Technical Indicators
| 30d moving avg. (EMA) | $28.63 |
| Relative strength (RSI) | 63 |
| MACD/Signal | 0.41/0.20 |
| Bollinger Bands (Upper/Lower) | $29.90/$27.40 |
| Short interest (% of AUM) | 1.9% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BMED |
Expenses vs. BMED |
ALTAR Score™ vs. BMED |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 39.2% | -10 bp | +2.2% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 38.5% | -25 bp | +6.0% |
| IYH | iShares U.S. Healthcare ETF | 37.4% | -45 bp | +5.1% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 37.0% | -45 bp | +5.8% |
| XLV | Health Care Select Sector SPDR | 36.5% | -77 bp | +5.9% |
| VHT | Vanguard Health Care ETF | 35.4% | -76 bp | +4.4% |
| FHLC | Fidelity MSCI Health Care Index ETF | 35.3% | -77 bp | +4.6% |
| IXJ | iShares Global Healthcare ETF | 34.7% | -43 bp | +5.8% |
| BBH | VanEck Biotech ETF | 32.3% | -50 bp | +3.5% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 32.2% | -10 bp | +0.4% |
Risk and Returns: BMED vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/30/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.9%
ALTAR SCORE™
9th
PERCENTILE
AVOID
ETFRC RATING
There are 730 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.6%. BMED's ALTAR Score™ is approximately -1.3 standard
deviations above the category average. This places BMED in the 9th percentile
among funds in the category.
Sell-Side Consensus
$33.54
PRICE TARGET
+9.0%
UPSIDE